Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1992 1
1996 1
2000 1
2001 1
2002 1
2008 1
2011 1
2012 1
2013 1
2015 3
2016 4
2017 4
2018 1
2021 6
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

28 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, Atyeo C, Loos C, Chandrashekar A, McMahan K, Tostanoski LH, Yu J, Gebre MS, Jacob-Dolan C, Li Z, Patel S, Peter L, Liu J, Borducchi EN, Nkolola JP, Souza M, Tan CS, Zash R, Julg B, Nathavitharana RR, Shapiro RL, Azim AA, Alonso CD, Jaegle K, Ansel JL, Kanjilal DG, Guiney CJ, Bradshaw C, Tyler A, Makoni T, Yanosick KE, Seaman MS, Lauffenburger DA, Alter G, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H, Barouch DH. Stephenson KE, et al. Among authors: de groot am. JAMA. 2021 Apr 20;325(15):1535-1544. doi: 10.1001/jama.2021.3645. JAMA. 2021. PMID: 33704352 Free PMC article. Clinical Trial.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H. Sadoff J, et al. Among authors: de groot am. N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13. N Engl J Med. 2021. PMID: 33440088 Free PMC article. Clinical Trial.
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, McMahan K, Jacob-Dolan C, Martinez DR, Chang A, Anioke T, Lifton M, Nkolola J, Stephenson KE, Atyeo C, Shin S, Fields P, Kaplan I, Robins H, Amanat F, Krammer F, Baric RS, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Struyf F, Douoguih M, van Hoof J, Schuitemaker H, Barouch DH. Alter G, et al. Among authors: de groot am. Nature. 2021 Aug;596(7871):268-272. doi: 10.1038/s41586-021-03681-2. Epub 2021 Jun 9. Nature. 2021. PMID: 34107529 Free PMC article. Clinical Trial.
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.
Tostanoski LH, Chandrashekar A, Patel S, Yu J, Jacob-Dolan C, Chang A, Powers OC, Sellers D, Gardner S, Barrett J, Sanborn O, Stephenson KE, Ansel JL, Jaegle K, Seaman MS, Porto M, Lok M, Spence B, Cayer K, Nase D, Holman S, Bradette H, Kar S, Andersen H, Lewis MG, Cox F, Tolboom JTBM, de Groot AM, Heerwegh D, Le Gars M, Sadoff J, Wegmann F, Zahn RC, Schuitemaker H, Barouch DH. Tostanoski LH, et al. Among authors: de groot am. NPJ Vaccines. 2022 Jan 10;7(1):2. doi: 10.1038/s41541-021-00427-z. NPJ Vaccines. 2022. PMID: 35013325 Free PMC article.
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.
Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, McMahan K, Liu J, Chandrashekar A, Patel S, Le Gars M, de Groot AM, Heerwegh D, Struyf F, Douoguih M, van Hoof J, Schuitemaker H. Barouch DH, et al. Among authors: de groot am. N Engl J Med. 2021 Sep 2;385(10):951-953. doi: 10.1056/NEJMc2108829. Epub 2021 Jul 14. N Engl J Med. 2021. PMID: 34260834 Free PMC article. No abstract available.
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.
Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, McMahan K, Liu J, Chandrashekar A, Patel S, Le Gars M, de Groot AM, Heerwegh D, Struyf F, Douoguih M, van Hoof J, Schuitemaker H. Barouch DH, et al. Among authors: de groot am. medRxiv. 2021 Jul 7:2021.07.05.21259918. doi: 10.1101/2021.07.05.21259918. Preprint. medRxiv. 2021. PMID: 34268527 Free PMC article. Updated.
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Sadoff J, Le Gars M, Brandenburg B, Cárdenas V, Shukarev G, Vaissiere N, Heerwegh D, Truyers C, de Groot AM, Jongeneelen M, Kaszas K, Tolboom J, Scheper G, Hendriks J, Ruiz-Guiñazú J, Struyf F, Van Hoof J, Douoguih M, Schuitemaker H. Sadoff J, et al. Among authors: de groot am. Vaccine. 2022 Jul 30;40(32):4403-4411. doi: 10.1016/j.vaccine.2022.05.047. Epub 2022 Jun 3. Vaccine. 2022. PMID: 35667914 Free PMC article.
Human milk extracellular vesicles target nodes in interconnected signalling pathways that enhance oral epithelial barrier function and dampen immune responses.
Zonneveld MI, van Herwijnen MJC, Fernandez-Gutierrez MM, Giovanazzi A, de Groot AM, Kleinjan M, van Capel TMM, Sijts AJAM, Taams LS, Garssen J, de Jong EC, Kleerebezem M, Nolte-'t Hoen ENM, Redegeld FA, Wauben MHM. Zonneveld MI, et al. Among authors: de groot am. J Extracell Vesicles. 2021 Mar;10(5):e12071. doi: 10.1002/jev2.12071. Epub 2021 Mar 10. J Extracell Vesicles. 2021. PMID: 33732416 Free PMC article.
28 results